Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Gamma and Camrelizumab in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07787273Phase 2Recruiting
- Sponsor
- Hefei Cancer Hospital, Chinese Academy of Sciences
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of interferon gamma-1b, camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hefei Cancer Hospital, Chinese Academy of Sciences. Started Mar 2026; status: recruiting.
02
Drugs
interferon gamma-1bcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07787273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787273.